protocol violations

Nektar Therapeutics faces class action lawsuit alleging REZOLVE-AA trial protocol violations and misstatements, affecting investors from February-December 2025.

Class action lawsuit filed against $NKTR alleging materially false statements regarding REZOLVE-AA trial enrollment protocols, claiming significant negative impact on trial integrity and results.

Class action lawsuit filed against Nektar Therapeutics alleging false statements about REZOLVE-AA trial enrollment protocols. Investors harmed between February-December 2025 can join case.

Nektar Therapeutics faces securities class action over alleged REZOLVE-AA trial disclosure failures. Investors who purchased shares February-December 2025 may seek recovery; lead plaintiff deadline is May 5, 2026.

Class action lawsuit filed against $NKTR alleging false statements about REZOLVE-AA trial enrollment and integrity. Lead plaintiff deadline set for May 5, 2026.

Class action lawsuit filed against Nektar Therapeutics alleging executives made false statements about REZOLVE-AA trial enrollment protocols, potentially overstating trial integrity and results.

Class action lawsuit filed against $NKTX alleging executives made false statements about REZOLVE-AA trial integrity. Investors urged to join by May 5, 2026 deadline.

Nektar Therapeutics faces securities lawsuit over REZOLVE-AA trial enrollment irregularities. Eligible investors have until May 5, 2026 to pursue compensation.

Class action lawsuit filed against Nektar Therapeutics alleging materially false statements regarding REZOLVE-AA trial enrollment protocols, claiming compromised trial integrity.

Nektar Therapeutics ($NKTR) faces class action lawsuit alleging false statements about REZOLVE-AA trial protocol adherence, threatening regulatory approval timelines and shareholder value.